cells/liter), differential with 72% segs, 17% bands, 2% lymphocytes, 2% monocytes; thrombocytopenia of 37 ϫ 10 9 cells/liter; anemia with hemoglobin of 11 ϫ 10 9 g/dl. The patient was treated initially with 500 mg imipenem-cilastatin every 8 h and 900 mg intravenous clindamycin every 8 h.
The bulla was aspirated, and Gram-negative rods were present on Gram stain. Gentamicin (80 mg) was added empirically. Surgical consultation was obtained to evaluate for possible myositis or necrotizing fasciitis.
Unfortunately, the patient's condition deteriorated, and he expired on the night of admission.
The bulla aspirate and 2 blood cultures grew Gram-negative rods. In our laboratory, the organism was oxidase negative, indole negative, and catalase positive. Biochemical results using the MicroScan Walkaway (Siemens, Memphis, TN) negative breakpoint combo panel 44 identified slightly different biotypes from 2 blood cultures (Table 1) . Biotype 1 gave a probability of Y. regensburgei of 98.79% and Hafnia alvei of 1.21%. Biotype 2 identified the organism with less confidence, with only 66.41% probability of Y. regensburgei and 33.59% of Hafnia alvei. The isolate was sent to the Associated Regional and University Pathologists (ARUP) laboratory (Salt Lake City, UT) for further identification and susceptibility testing. A partial ribosomal sequence provided 3 possible identities to the isolate-Yokenella, Klebsiella, or Morganella. Subsequently, ARUP tested the isolate using the BD Phoenix Automated Microbiology System (Franklin Lakes, NJ), which identified Yokenella regensburgei with 99% probability through a series of biochemical assays (Table 1) . Based on this series of tests, the organism most closely resembled Y. regensburgei. Partial 16S PCR primer sequencing or full-length ribosomal sequencing of the isolate with subsequent comparison to a curated microbiology database may have definitively identified the organism to the genus and species levels, respectively. Unfortunately, the isolate is no longer available for further testing.
Susceptibility testing at RWJUH was performed using the MicroScan Walkaway negative breakpoint combo 44 panel, with MIC results as follows: amikacin, Յ16; aztreonam, 8; ceftazidime, Յ1; ciprofloxacin, Յ1; gentamicin, Յ4; imipenem-cilastatin, Յ4; levofloxacin, Յ2; meropenem, Յ4; piperacillin-tazobactam, Յ16; tobramycin, Յ4.
At ARUP, the organism failed to grow for susceptibilities in the Phoenix system; therefore, disk diffusion zone sizes were measured and a software program extrapolated MIC values. The MIC results are as follows: amikacin, 2; aztreonam, Յ2; ceftazidime, 2; ciprofloxacin, Յ0.12; gentamicin, 1; levofloxacin, 0.12; meropenem, 0.5; piperacillin-tazobactam, 4; tobramycin, 1.
Yokenella regensburgei is a member of the family Enterobacteriaceae, rarely encountered in clinical practice. The organism was first identified by DNA hybridization in 1984 by the National Health Institute of Japan (1) . The following year, the Centers for Disease Control and Prevention proposed the name Koserella trabulsii (2) . In an independent study, it was proven that Y. regensburgei and K. trabulsii are objective synonyms and that Yokenella regensburgei has priority, as it was published first (3) .
The organism appears to primarily belong to bacterial flora of insects, although it has been isolated from the respiratory tract, wounds, urine, and feces of humans (4). It is unclear if the organism has been an actual cause of infection when isolated or more of a colonizer in humans.
Y. regensburgei closely resembles Hafnia alvei biochemically and has been misidentified as Salmonella enterica by automated systems as well (5) . It has been hypothesized that infections due to Y. regensburgei have been underestimated because of misidentification of the bacteria. Stock et al. studied susceptibility patterns and biochemical properties to help distinguish it from H. alvei (6) . Y. regensburgei is noted to be intrinsically resistant to azithromycin and some beta-lactam antibiotics, to possess ampC genes, and to express highly inducible, potent beta-lactamases. Y. regensburgei is weakly catalase positive and unable to produce hydroxyproline amidase, tripeptidase, or proline deaminase. In the study, 9 of 10 strains expressed maltosidase and fermented melibiose and myo-inositol (6). The Voges-Proskauer test was negative, and all strains failed to produce acid from glycerol (7). Jachymek et al. discovered novel trisaccharide repeating units of bacterial O antigens that are characteristic and unique to the Y. regensburgei species (8).
Two articles described cases suggesting possible pathogenic Y. regensburgei. The first case describes a patient with a knee wound and a history of alcohol abuse. He was treated with amikacin, and no further data were available regarding the patient's clinical course. In the second case, a 35-year-old woman who abused alcohol suffered from an upper gastrointestinal bleed. During her hospital course, although she had no signs of sepsis, such as fever or chills, a blood culture grew Y. regensburgei (4). The authors suggest that both patients were immunocompromised due to alcohol abuse. Another article describes a patient with membranous glomerulonephritis on immunosuppressive therapy with highdose steroids (prednisolone total of 30 mg per day) and cyclophosphamide. He subsequently developed a soft tissue infection after abrasions to his leg were contaminated with soil. He experienced fevers with chills, and blood cultures grew Y. regensburgei. The patient was treated with ceftriaxone for 3 weeks, and he was discharged from the hospital in stable condition.
In the case presented here, the patient was immunocompromised secondary to his autologous stem cell transplant and use of corticosteroids for liver disease. From the limited cases reported and this case, we hypothesize that Y. regensburgei may be an op- 
portunistic pathogen with a propensity to infect immunocompromised patients, perhaps favoring those with liver disease. The patient reported here had a skin and soft tissue infection that progressed rapidly and mimicked Streptococcus pyogenes cellulitis with lymphangitic spread. A literature review of patients with Gram-negative cellulitis (9-16) revealed only one case with lymphangitic streaking. The implicated organism was Plesiomonas shigelloides. The tempo of infection in the case we present was rapid and alarming but was possibly due to the patient's impaired host defense since the organism was susceptible to both imipenem-cilastatin and gentamicin.
In summary, we report a case of Y. regensburgei septicemia due to soft tissue infection in an immunocompromised host, leading to the rapid demise of the patient. Y. regensburgei may be an opportunistic pathogen with a predilection to infect immunocompromised hosts and patients with impaired liver function. 
